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for intervention and treatment, and also production loss of
patients as indirect costs. RESULTS: A total of 185 question-
naires on SF-36 and EQ-5D were returned (88 stepped, 97 ordi-
nary). There was no statistically signiﬁcant difference between
the scores of two groups. The expected costs a patient in the deci-
sion model were estimated as US$4072 (US$ = JPY110) for the
stepped care, and US$2695 for the ordinary care with the dis-
count of 3% a year in three years. The incremental cost-
effectiveness ratio was US$17,636 in terms of cost per patient
prevented from becoming Type-2 diabetes. CONCLUSIONS:
The analysis on the JDPP intermediate report suggested that the
stepped care resulted in increased costs for prevention compar-
ing to the ordinary care in three years, maintaining the same level
of QOLs in both groups.
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OBJECTIVES: Pioglitazone (PIO), a PPARã-Agonist has been
approved in Germany for treatment of patients with Type-2-
diabetes in mono-and combination therapy with either meformin
(MET) or sulfonylurea. Long-term studies with a treatment
period of 104 weeks involving 1197 patients comparing PIO
with Gliclazide (GLIC) have recently been published. These
studies revealed a superior effect of PIO in sustaining the HbA1C
reduction compared to GLIC. Whether this translates to beneﬁts
with regard to cost-effectiveness is currently unknown.
METHODS: This study compared the clinical effects and costs
of PIO (15–45mg) combination therapy (MET) and 30–45mg
monotherapy with GLIC + MET or GLIC monotherapy, respec-
tively. The validated IMIB Markov diabetes model was adapted.
The mean time transferring a patient to insulin therapy (MIT),
life expectancy (LE and ÄLE), the related NNT to avoid 1
event/1 death and the incremental cost-effectiveness as cost per
life year gained (C/LYG) discounted at 0% and 5% were calcu-
lated. RESULTS: In monotherapy PIO was associated with a
higher MIT 11.70 vs. 11.39 years and a LE of 15.90 vs. 15.45
years (ÄLE: 0.44 years) vs. GLIC. For PIO vs. GLIC the NNT
to avoid 1 event and 1 death were 32 and 54, respectively. When
leaving the C/LYG undiscounted, PIO dominated GLIC and
amounted to 2997€ (5%) vs. GLIC. In combination therapy PIO
+ MET was associated with a higher MIT 9.73 vs. 9.23 years
and a LE of 15.58 vs. 14.94 years (ÄLE: 0.64 years) compared
to GLIC + MET. For PIO + MET vs. GLIC + MET the NNT to
avoid 1 event and 1 death were 28 and 36, respectively. The
C/LYG for PIO + MET was calculated with 1445€ (0%) and
5480€ (5%) vs. GLIC + MET. CONCLUSIONS: The study indi-
cates that PIO in mono, as well as in combination therapy, is
preferable in terms of health outcomes and cost-effectiveness
compared to GLIC in patients with Type-2-diabetes.
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OBJECTIVES: Glucophage®XR is a new extended-release for-
mulation of metformin which permits once-daily medication.
Clinical studies show that Glucophage®XR demonstrate the
same antihyperglycemic efﬁcacy as immediate-release metformin
(Glucophage®). However, in a retrospective chart review,
patients with type 2 diabetes experienced fewer GI side effects
and comparable or better glycemic control, based on HbA1C
measurement, when switched from Glucophage® to Glu-
cophage®XR. Mean HbA1c values were 7.8%-points before the
switch and 7.5%-points afterwards. The CORE Diabetes Model,
a peer-reviewed, validated, model was used to project the long-
term cost-effectiveness of switching patients from Glucophage®
to Glucophage®XR. METHODS: The CORE Diabetes model
employs standard Markov/Monte Carlo simulation techniques
to describe the long-term incidence and progression of diabetes-
related complications. Transition probabilities were derived from
major diabetes studies. Clinical effects of switching from Glu-
cophage® to Glucophage®XR were derived from a retrospec-
tive database study. The analysis was performed using published
UK-speciﬁc costs, health care resource utilization, clinical data
and recommended discount rates of 3.5% for costs and clinical
outcomes. A lifetime horizon and NHS payer perspective was
taken. Only direct costs were considered. Sensitivity analyses
were performed. RESULTS: Switching patients from Glu-
cophage® to Glucophage®XR was projected to improve life
expectancy by 0.10 years, quality-adjusted life expectancy by
0.09 years, and decrease overall lifetime costs by £201/patient.
Results were most sensitive to variations in assumptions about
changes in HbA1c when patients are switched from Glu-
cophage® to Glucophage®XR, and the relative costs of treat-
ment. CONCLUSIONS: In real life, due to improved tolerability,
compliance, and glycemic control, switching patients from Glu-
cophage® to Glucophage®XR may improve longterm patient
outcomes and lead to overall cost savings.
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OBJECTIVES: In the province of Styria, Austria, a structured
patient education program for patients with type-2 diabetes was
established in the year 2000. In this open label, prospective
cohort study (n = 1150) follow-up data after one year have been
analysed to document the potential effects over 10 years using
the CORE-Diabetes Model, a validated, peer reviewed simula-
tion model. Patients outcomes and total costs were calculated.
METHODS: A Styria-wide patient education program for type-
2 diabetes was established for general practitioners to improve
treatment outcomes in diabetes care. The program is funded by
the public health care system and a standardised documentation
at baseline and after one year was used. Intermediate results after
one year were incorporated in the CORE diabetes model and
linked with Austria speciﬁc cost data. Monte-Carlo-Simulation
(n = 5.000) over ten years projected long term effects of single
patient education. A virtual control group was assumed to be
treated like general Styrian diabetic population. Discount rate
was 5 % annually. RESULTS: The average life expectancy
increased by 0.29 years (7.32 ± 3.48 vs. 7.03 ± 3.5) under edu-
cation, the total costs over ten years decreased by 774€ per
patient (20,496€ ± 30,335€ vs. 21,270€ ± 37,917€) or 3.8%.
Patient education leads to improved foot care and retinal screen-
